European Union trade negotiators are currently in Ottawa to finalize the details of a comprehensive trade agreement with Canada. It was with great interest, therefore, that I read this:
A recent study by Professor Aidan Hollis of the University of Calgary and Paul Grootendorst of the University of Toronto titled, The Canada-European Union Comprehensive Economic & Trade Agreement: An Economic Impact Assessment of Proposed Pharmaceutical Intellectual Property Provisions, estimates that the adoption of the EU’s drug patent system proposals would add nearly $3- billion to Canada’s prescription drug bill.
Read more here.
The Past Speaks 